A#1746 companion for RA Like plenary for PsA, PBO response incr w time 1%/yr More trials in less affluent countries may be related to increasing PBO response in trials Possible reason: access to health care improves PBO in less affluent areas @RheumNow #ACR24 https://t.co/S3LffF8vPH

• https://twitter.com/ericdeinmd/status/1857803974922903912

RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi). Prioritize statins for heart health in RA! #ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d

• https://x.com/JihaRheum/status/1858252521044893744/photo/1
• https://x.com/JihaRheum/status/1858252521044893744/photo/1

The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x

• https://x.com/RHEUMarampa/status/1858252752427626764/photo/1

A#1745 Post-hoc ORAL Surveillance - statin <1/4 on a statin, only 53% h/o ASCVD on statin Incr in LDL was less on Tofa pts on statin Among those on b/l statins, there is no incr risk compare to TNFi, esp pts h/o ASCVD If high risk on tofa, statin helps! @RheumNow #ACR24 #ACRBest https://t.co/7MGgUk7tfI

• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1

Wallace et al. Case control study. 648 cases 1241 controls. Cumulative glucocorticoid dose and risk MACE. Dose dependent increase in risk, OR 1.01 for 10% increase GC, 1.21 for 10-fold increase GC. @RheumNow #ACR24 Abstr#1719 https://t.co/wraiWOl1dv https://t.co/feht58RDNc

• Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a…
• https://x.com/RichardPAConway/status/1858248746078785887/photo/1

Single cell TCR sequence study explores the limitations of TRBV9-depleting therapies in axial spondyloarthritis. Key findings: - Identified a clonally expanded TRBV5-5+ TCR in HLA-B27+ acute anterior uveitis. - Alternative TRBVs may retain pathogenicity and evade anti-TRBV9… https://t.co/Aj8oslsTNX

• https://x.com/i/web/status/1858246230763253795

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

A#1744 AI for RA to improve scheduling in UK 39% pts meet quality metric for early intervention Input: RF, CRP, CCP, gender, age -> 51% accuracy (compare to first appt clinical accur 46%) Focusing on highest risk -> 88% accuracy -> 50% wait time for high-risk pts #ACR24 @RheumNow

Strive for remission (CDAI ≤2.8) to achieve better functional outcomes in RA #ACR24 @RheumNow ABST#1743 https://t.co/qpsTF54rmW

• https://x.com/JihaRheum/status/1858243713019044198/photo/1

In a cohort of >17,000 European pts w/ axSpA: -bDMARD naïve pts starting TNFi or IL-17Ai were more likely to achieve LDA than TNF-experienced. -Higher time to achieve LDA and shorter durability in pts with prior TNFi use. Abst#1756 #ACR24 @RheumNow

Further evidence for risk of #MACE with cumulative GC use in RA In a national cohort of pts with RA: ⬆️cumulative GC exposure associated with ⬆️odds of MACE, regardless of baseline MACE risk Ab1719 #ACR24 @RheumNow https://t.co/RmxokfBXYX

• https://x.com/DrMiniDey/status/1858243461356687493/photo/1

Study revealing the Uterine-Joint Axis in female axial spondyloarthritis, highlighting dysbiosis and subclinical uterine inflammation as key factors in disease pathogenesis. Key findings: - Distinct microbiota profiles in AxSpA patients vs. healthy controls. - Significant genital… https://t.co/Cl12ELdjI2

• https://x.com/i/web/status/1858238682848784496

A#1743 Are there benefits of getting LDA to remission? Remission CDAI <2.8, VLDA 2.8-6, LDA 6-10 After 1 yr f/u of LDA, 45% Rem, 40 VLDA, 16 LDA Not in remiss - higher BMI, longer duration, higher resource utilization, worse PRO No clear diff bw remission & VLDA #ACR24 @RheumNow https://t.co/ut7c52JVDr

• https://x.com/ericdeinmd/status/1858241720921809287/photo/1
• https://x.com/ericdeinmd/status/1858241720921809287/photo/1
• https://x.com/ericdeinmd/status/1858241720921809287/photo/1

Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT

• Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Ar…
• https://x.com/RichardPAConway/status/1858242203380003024/photo/1